Clinical trial NCT03891953: Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors.
Official title: A Phase I/Ib, Open-label, Multi-center, Study of DKY709 as a Single Agent and in Combination With PDR001 in Patients With Advanced Solid Tumors
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: PHASE1
Conditions: Carcinoma, Non-Small-Cell Lung
Melanoma
Nasopharyngeal Carcinoma
Microsatellite Stable Colorectal Cancer
Triple Negative Breast Cancer
Keywords: Non-small Cell Lung Cancer
Melanoma
Nasopharyngeal Carcinoma
Microsatellite Stable Colorectal Cancer
Triple Negative Breast Cancer
Lead sponsor: Novartis
Sponsor class: INDUSTRY
First posted: 2019-03-27
Enrollment: 98
Sex: ALL
Minimum age (years): 18
Maximum age (years): 100
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This is a phase I/Ib, open label study. The escalation portion will characterize the safety and tolerability of DKY709 and DKY709 in combination with PDR001 in subjects with NSCLC or melanoma who have received prior anti-PD-1/PD-L1 therapy, or subjects with NPC. After the determination of the MTD/RD for a particular treatment arm, dose expansion will further assess safety, tolerability, PK/PD, and anti-tumor activity of each regimen at the MTD/RD.


Eligibility criteria: Inclusion Criteria:

1. Signed informed consent must be obtained prior to participation in the study.
2. Patients must be ≥18 years of age at the time of informed consent form (ICF) signature.
3. Patients with advanced/metastatic cancer who have progressed despite having received standard therapy in the metastatic setting or are intolerant to standard therapy, and for whom no effective standard therapy is available
4. In expansion: patient with measurable disease as determined by RECIST version 1.1,
5. Dose escalation, patients must fit into one of the following groups:

   * NSCLC, previously treated with an anti-PD-1/PD-L1 therapy
   * Cutaneous Melanoma, previously treated with an anti-PD-1/PD-L1 therapy
   * NPC

   Dose expansion part, patients must fit into one of the following groups:
   * NSCLC with historic documentation of PD-L1 ≥ 1%. Patients must have progressive disease after having experienced at least 4 months of investigator-assessed disease stability or response on prior anti-PD-L1-containing therapy
   * Cutaneous Melanoma, previously treated with anit-PD-1/PD-L1 therapy. Patients should have documented progression following anti-PD-1/PD-L1 therapy.
   * NPC, naive to anti-PD-1/PD-L1 therapy
   * mssCRC, naive to anti-PD-1/PD-L1 therapy
   * TNBC, naive to anti-PD-1/PD-L1 therapy
6. ECOG Performance Status ≤ 1
7. Patients must have a site of disease amenable to core needle biopsy, and be a candidate for tumor biopsy according to the treating institution's guidelines. Patients must be willing to undergo a new tumor biopsy at baseline, and during therapy on the study. Exceptions may be considered after documented discussion with Novartis.

Exclusion Criteria:

1. Presence of symptomatic central nervous system (CNS) metastases, or CNS metastases that require local CNS-directed therapy (such as radiotherapy or surgery), or increasing doses of corticosteroids within 2 weeks prior to study entry. Patients with treated brain metastases should be neurologically stable for at least 4 weeks prior to study entry and off steroids for at least 2 weeks before administration of any study treatment.
2. History of severe hypersensitivity reactions to any ingredient of study drug(s) or other mAbs and/or their excipients.
3. Patient with out of range laboratory values defined as:

   * Creatinine clearance (calculated using Cockcroft-Gault formula, or measured) \< 40 mL/min
   * Total bilirubin \> 1.5 x ULN, except for patients with Gilbert's syndrome who are excluded if total bilirubin \> 3.0 x ULN or direct bilirubin \> 1.5 x ULN
   * Alanine aminotransferase (ALT) \> 3 x ULN, except for patients that have tumor involvement of the liver, who are excluded if ALT \> 5 x ULN
   * Aspartate aminotransferase (AST) \> 3 x ULN, except for patients that have tumor involvement of the liver, who are excluded if AST \> 5 x ULN
   * Absolute neutrophil count (ANC) \< 1.0 x 109/L
   * Platelet count \< 75 x 109/L (growth factor or transfusion support may not be used to meet entry criterion)
   * Hemoglobin (Hgb) \< 8 g/dL (growth factor or transfusion support may not be used to meet entry criterion)
   * Magnesium, calcium or phosphate abnormality CTCAE \> grade 1
   * Potassium abnormality CTCAE ≥ grade 1; supplementation to meet eligibility criteria is acceptable
4. Clinically significant cardiac disease or impaired cardiac function, including any of the following:

   * Clinically significant and/or uncontrolled heart disease such as congestive heart failure requiring treatment (NYHA grade ≥ 2), uncontrolled hypertension or clinically significant arrhythmia
   * On screening: QTcF \> 450 msec (male), or \> 460 msec (female)
   * QTc not assessable
   * Congenital long QT syndrome
   * History of familial long QT syndrome or known family history of as Torsades de Pointes
   * Acute myocardial infarction or unstable angina pectoris \< 3 months prior to study entry

Primary outcomes:
measure: Safety of DKY709 single agent treatment or DKY709 in combination with PDR001.
timeFrame: 24 months
measure: incidence of Dose Limiting Toxicities (DLTs)
timeFrame: 1 Month
measure: Tolerability of DKY709 single agent treatment or DKY709 in combination with PDR001.
timeFrame: 24 months
Secondary outcomes:
measure: AUC of DKY709 and PDR001
timeFrame: 24 months
measure: Cmax of DKY709 and PDR001
timeFrame: 24 months
measure: Tmax of DKY709 and PDR001
timeFrame: 24 months
measure: Half-life of DKY709 and PDR001
timeFrame: 24 months
measure: Progression Free Survival (PFS)
timeFrame: 24 months
measure: Best Overall Response (BOR)
timeFrame: 24 months
measure: Duration of Response (DOR)
timeFrame: 24 months
measure: Time to Progression (TTP)
timeFrame: 24 months
Other outcomes:
Locations:
city: Boston
country: United States
facility: Massachusetts General Hospital
state: Massachusetts
city: Boston
country: United States
facility: Dana Farber Cancer Institute
state: Massachusetts
city: Nashville
country: United States
facility: Sarah Cannon Research Institute
state: Tennessee
city: Dresden
country: Germany
facility: Novartis Investigative Site
city: Essen
country: Germany
facility: Novartis Investigative Site
city: Hong Kong
country: Hong Kong
facility: Novartis Investigative Site
city: Chuo ku
country: Japan
facility: Novartis Investigative Site
state: Tokyo
city: Barcelona
country: Spain
facility: Novartis Investigative Site
state: Catalunya
city: Taipei
country: Taiwan
facility: Novartis Investigative Site
Study officials:
References: